CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,260 enrolled
Drug / intervention
Olopatadine hydrochloride 0.6% nasal spray (PATANASE) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00789555
NCT00789555Phase 4Completed
CompareCT.gov

Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis

Alcon Research·interventional·Posted Nov 13, 2008·Updated Feb 8, 2018

In Brief

A Phase 4 clinical trial evaluating Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, and 1 other intervention for Perennial Allergic Rhinitis. Completed, enrolled 1,260 participants across 1 site.

Detailed Summary

The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 13, 2008
Enrollment StartNov 1, 2008
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.6 years ago

Interventions

Olopatadine hydrochloride 0.6% nasal spray (PATANASE)drug

Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Olopatadine nasal spray vehicle, pH 3.7other

Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Olopatadine nasal spray vehicle, pH 7.0other

Two sprays in each nostril twice a day (morning and evening) for up to 12 months